{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T12:35:48Z","timestamp":1783082148552,"version":"3.54.6"},"reference-count":29,"publisher":"MDPI AG","issue":"20","license":[{"start":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T00:00:00Z","timestamp":1666137600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Mahidol University and the International Decision Support Initiative (iDSI)","doi-asserted-by":"publisher","award":["OPP1087363"],"award-info":[{"award-number":["OPP1087363"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Bill &amp; Melinda Gates Foundation","award":["OPP1087363"],"award-info":[{"award-number":["OPP1087363"]}]},{"name":"UK Department for International Development","award":["OPP1087363"],"award-info":[{"award-number":["OPP1087363"]}]},{"name":"Rockefeller Foundation","award":["OPP1087363"],"award-info":[{"award-number":["OPP1087363"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJERPH"],"abstract":"<jats:p>A tuberculin skin test (TST) or interferon-gamma release assay (IGRA) can be used to screen for latent tuberculosis infection (LTBI). Due to its low cost, TST has been used particularly in underdeveloped countries. The limitations of TST were poor specificity in populations with a high prevalence of Bacille Calmette-Gu\u00e9rin (BCG) vaccination and variability of test readers. IGRA is used as an alternative to TST in settings where higher costs can be supported. The lack of studies conducted in high TB incidence countries since previous review, and using relevant assessment tools of the quality appraisal make the need for updated studies and a more comprehensive systematic review. This study aimed to conduct a systematic review of published economic evaluations of screening strategies for LTBI in contacts of TB patients, assess the quality of these studies, and compare the assessment results related to a country\u2019s income level in order to provide information to other countries. The databases were searched in January 2022 including MEDLINE and Scopus. Two independent reviewers evaluated the included studies based on eligibility criteria, data extraction, and quality assessment. Eleven economic evaluations of LTBI diagnostic tests in TB contacts were included. Most studies were conducted in high-income countries (91%) and used cost-effectiveness analysis methods (73%). The quality assessment of reporting and data sources was appropriate, ranging from 71% to 89%. Interventions varied from study to study. The outcomes were cost per life years gained (27%), cost per quality-adjusted life year gained (27%), cost per TB case prevented (36%), and cost per close contact case (10%). In high-income countries which were not countries with high TB burden, the use of IGRA alone for screening TB contacts was cost-effective, whereas TST was cost-effective in only two studies. In comparison to TST, IGRA could reduce false-positive results, resulting in fewer patients undergoing TB treatment and preventive treatment.<\/jats:p>","DOI":"10.3390\/ijerph192013529","type":"journal-article","created":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T20:32:23Z","timestamp":1666211543000},"page":"13529","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Economic Evaluation of Screening Strategy for Latent Tuberculosis Infection (LTBI) in Contacts of Tuberculosis Patients: Systematic Review and Quality Assessment"],"prefix":"10.3390","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6646-1921","authenticated-orcid":false,"given":"Panida","family":"Yoopetch","sequence":"first","affiliation":[{"name":"Mahidol University Health Technology Assessment (MUHTA) Graduate Program, Mahidol University, Bangkok 10400, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natthakan","family":"Chitpim","sequence":"additional","affiliation":[{"name":"Social, Economic, and Administrative Pharmacy Graduate Program, Department of Pharmacy, Faculty of Pharmacy, Mahidol University, Bangkok 10400, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiraphun","family":"Jittikoon","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Faculty of Pharmacy, Mahidol University, Bangkok 10400, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanvisa","family":"Udomsinprasert","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Faculty of Pharmacy, Mahidol University, Bangkok 10400, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8256-2167","authenticated-orcid":false,"given":"Montarat","family":"Thavorncharoensap","sequence":"additional","affiliation":[{"name":"Mahidol University Health Technology Assessment (MUHTA) Graduate Program, Mahidol University, Bangkok 10400, Thailand"},{"name":"Social Administrative Pharmacy Division, Department of Pharmacy, Faculty of Pharmacy, Mahidol University, Bangkok 10400, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2448-3954","authenticated-orcid":false,"given":"Sitaporn","family":"Youngkong","sequence":"additional","affiliation":[{"name":"Mahidol University Health Technology Assessment (MUHTA) Graduate Program, Mahidol University, Bangkok 10400, Thailand"},{"name":"Social Administrative Pharmacy Division, Department of Pharmacy, Faculty of Pharmacy, Mahidol University, Bangkok 10400, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naiyana","family":"Praditsitthikorn","sequence":"additional","affiliation":[{"name":"Department of Disease Control, Ministry of Public Health, Nonthaburi 11000, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surakameth","family":"Mahasirimongkol","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Medical Genetics Center, Medical Life Sciences Institute, Ministry of Public Health, Nonthaburi 11000, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usa","family":"Chaikledkaew","sequence":"additional","affiliation":[{"name":"Mahidol University Health Technology Assessment (MUHTA) Graduate Program, Mahidol University, Bangkok 10400, Thailand"},{"name":"Social Administrative Pharmacy Division, Department of Pharmacy, Faculty of Pharmacy, Mahidol University, Bangkok 10400, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,10,19]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2021). Global Tuberculosis Report 2021, WHO."},{"key":"ref_2","unstructured":"World Health Organization (2018). Latent Tuberculosis Infection: Updated and Consolidated Guidelines for Programmatic Management, World Health Organization. Report No.: 9241550236."},{"key":"ref_3","unstructured":"World Health Organization (2015). Guidelines on the Management of Latent Tuberculosis Infection, World Health Organization."},{"key":"ref_4","unstructured":"World Health Organization (2019). South-East Asia Regional Action Plan on Programmatic Management of Latent Tuberculosis Infection, World Health Organization."},{"key":"ref_5","unstructured":"Raviglione, M., and Director, G. (2013). Global Strategy and Targets for Tuberculosis Prevention, Care and Control after 2015, World Health Organization."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S1473-3099(19)30059-3","article-title":"Latent tuberculosis infection: Diagnostic tests and when to treat","volume":"19","author":"Petersen","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"781","DOI":"10.3855\/jidc.1689","article-title":"The stability of human, bovine and avian tuberculin purified protein derivative (PPD)","volume":"5","author":"Maes","year":"2011","journal-title":"J. Infect. Dev. Ctries."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.ijid.2019.01.048","article-title":"Tuberculin skin test\u2013Outdated or still useful for Latent TB infection screening?","volume":"80","author":"Gualano","year":"2019","journal-title":"Int. J. Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"340","DOI":"10.7326\/0003-4819-146-5-200703060-00006","article-title":"Meta-analysis: New tests for the diagnosis of latent tuberculosis infection: Areas of uncertainty and recommendations for research","volume":"146","author":"Menzies","year":"2007","journal-title":"Ann. Intern. Med."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Doan, T.N., Eisen, D.P., Rose, M.T., Slack, A., Stearnes, G., and McBryde, E.S. (2017). Interferon-gamma release assay for the diagnosis of latent tuberculosis infection: A latent-class analysis. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0188631"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1136\/thoraxjnl-2015-207811","article-title":"Effect of immunosuppressive therapy on interferon \u03b3 release assay for latent tuberculosis screening in patients with autoimmune diseases: A systematic review and meta-analysis","volume":"71","author":"Wong","year":"2016","journal-title":"Thorax"},{"key":"ref_12","unstructured":"World Health Organization (2011). Use of Tuberculosis Interferon-Gamma Release Assays (IGRAs) in Low- and Middle- Income Countries: Policy Statement, WHO."},{"key":"ref_13","unstructured":"World Health Organization (2020). Global Tuberculosis Report 2020, WHO."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1472-6963-11-247","article-title":"Systematic review of cost and cost-effectiveness of different TB-screening strategies","volume":"11","author":"Nienhaus","year":"2011","journal-title":"BMC Health Serv. Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1017\/S0266462321001732","article-title":"Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: Updated reporting guidance for health economic evaluations","volume":"38","author":"Husereau","year":"2022","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1258\/135581905774414187","article-title":"Use of evidence in decision models: An appraisal of health technology assessments in the UK since 1997","volume":"10","author":"Cooper","year":"2005","journal-title":"J. Health Serv. Res. Policy"},{"key":"ref_17","unstructured":"World Bank Group (2022, September 16). World Bank Country and Lending Groups 2022. Available online: https:\/\/data.worldbank.org\/."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"496","DOI":"10.5588\/ijtld.17.0718","article-title":"Cost-effectiveness of contact screening strategies for tuberculosis among high-school adolescents in South Korea","volume":"22","author":"Sohn","year":"2018","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Steffen, R.E., Caetano, R., Pinto, M., Chaves, D., Ferrari, R., Bastos, M., de Abreu, S.T., Menzies, D., and Trajman, A. (2013). Cost-effectiveness of Quantiferon\u00ae-TB Gold-in-Tube versus tuberculin skin testing for contact screening and treatment of latent tuberculosis infection in Brazil. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0059546"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1164\/rccm.201101-0181OC","article-title":"Priorities for screening and treatment of latent tuberculosis infection in the United States","volume":"184","author":"Linas","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Pooran, A., Booth, H., Miller, R.F., Scott, G., Badri, M., Huggett, J.F., Rook, G., Zumla, A., and Dheda, K. (2010). Different screening strategies (single or dual) for the diagnosis of suspected latent tuberculosis: A cost effectiveness analysis. BMC Pulm. Med., 10.","DOI":"10.1186\/1471-2466-10-7"},{"key":"ref_22","first-page":"471","article-title":"Cost-effectiveness of QuantiFERON\u00ae\u2014TB test vs. tuberculin skin test in the diagnosis of latent tuberculosis infection","volume":"14","author":"Atsou","year":"2010","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1016\/j.rmed.2009.07.008","article-title":"Enhanced cost-benefit analysis of strategies for LTBI screening and INH chemoprevention in Germany","volume":"103","author":"Diel","year":"2009","journal-title":"Respir. Med."},{"key":"ref_24","first-page":"1414","article-title":"Cost-effectiveness of a new interferon-based blood assay, QuantiFERON\u00ae-TB Gold, in screening tuberculosis contacts","volume":"12","author":"Marra","year":"2008","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/BF03256289","article-title":"Cost effectiveness of interferon-gamma release assay for tuberculosis contact screening in Japan","volume":"12","author":"Kowada","year":"2008","journal-title":"Mol. Diagn. Ther."},{"key":"ref_26","first-page":"16","article-title":"Interferon-gamma release assays and TB screening in high-income countries: A cost-effectiveness analysis","volume":"11","author":"Oxlade","year":"2007","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1183\/09031936.00145906","article-title":"Cost-effectiveness of interferon-\u03b3 release assay testing for the treatment of latent tuberculosis","volume":"30","author":"Diel","year":"2007","journal-title":"Eur. Respir. J."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1378\/chest.06-2728","article-title":"Cost-effectiveness of interferon-gamma release assay screening for latent tuberculosis infection treatment in Germany","volume":"131","author":"Diel","year":"2007","journal-title":"Chest"},{"key":"ref_29","unstructured":"Division of Tuberculosis Elimination NCfH, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention (2022, September 01). Treatment Regimens for Latent TB Infection (LTBI) 2020 [updated February 13, 2020], Available online: https:\/\/www.cdc.gov\/tb\/topic\/treatment\/ltbi.htm."}],"container-title":["International Journal of Environmental Research and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1660-4601\/19\/20\/13529\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:57:09Z","timestamp":1760144229000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1660-4601\/19\/20\/13529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,19]]},"references-count":29,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["ijerph192013529"],"URL":"https:\/\/doi.org\/10.3390\/ijerph192013529","relation":{},"ISSN":["1660-4601"],"issn-type":[{"value":"1660-4601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,19]]}}}